DELCATH SYSTEMS, INC.DCTHEarnings & Financial Report
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in th...
DCTH Q4 FY2025 Key Financial Metrics
Revenue
$20.7M
Gross Profit
$17.7M
Operating Profit
$-2.2M
Net Profit
$-1.9M
Gross Margin
85.5%
Operating Margin
-10.5%
Net Margin
-9.1%
YoY Growth
37.3%
EPS
$-0.05
DELCATH SYSTEMS, INC. Q4 FY2025 Financial Summary
DELCATH SYSTEMS, INC. reported revenue of $20.7M (up 37.3% YoY) for Q4 FY2025, with a net profit of $-1.9M (up 44.2% YoY) (-9.1% margin). Cost of goods sold was $3.0M, operating expenses totaled $19.9M.
Key Financial Metrics
| Total Revenue | $20.7M |
|---|---|
| Net Profit | $-1.9M |
| Gross Margin | 85.5% |
| Operating Margin | -10.5% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
DELCATH SYSTEMS, INC. Q4 FY2025 revenue of $20.7M breaks down across 2 segments, led by HEPZATOKIT at $19.1M (91.9% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| HEPZATOKIT | $19.1M | 91.9% |
| CHEMOSAT | $1.7M | 8.1% |
DELCATH SYSTEMS, INC. Revenue by Segment — Quarterly Trend
DELCATH SYSTEMS, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as HEPZATOKIT and CHEMOSAT) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| HEPZATOKIT | $19.1M | $19.3M | $22.5M | $18.0M |
| CHEMOSAT | $1.7M | $1.3M | $1.7M | $1.8M |
DELCATH SYSTEMS, INC. Annual Revenue by Year
DELCATH SYSTEMS, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $85.2M).
DELCATH SYSTEMS, INC. Quarterly Revenue & Net Profit History
DELCATH SYSTEMS, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $20.7M | +37.3% | $-1.9M | -9.1% |
| Q3 FY2025 | $20.6M | +83.6% | $830.0K | 4.0% |
| Q2 FY2025 | $24.2M | +211.0% | $2.7M | 11.2% |
| Q1 FY2025 | $19.8M | +530.3% | $1.1M | 5.4% |
| Q4 FY2024 | $15.1M | +2701.5% | $-3.4M | -22.5% |
| Q3 FY2024 | $11.2M | +2480.6% | $1.9M | 16.6% |
| Q2 FY2024 | $7.8M | +1468.9% | $-13.7M | -176.9% |
| Q1 FY2024 | $3.1M | +425.8% | $-11.1M | -354.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $7.8M | $11.2M | $15.1M | $19.8M | $24.2M | $20.6M | $20.7M |
| YoY Growth | 425.8% | 1468.9% | 2480.6% | 2701.5% | 530.3% | 211.0% | 83.6% | 37.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $36.1M | $33.9M | $31.7M | $76.6M | $87.3M | $116.9M | $124.3M | $123.6M |
| Liabilities | $21.5M | $29.7M | $23.1M | $7.8M | $7.1M | $11.9M | $9.4M | $12.4M |
| Equity | $14.6M | $4.2M | $8.6M | $68.7M | $80.2M | $105.0M | $114.8M | $111.2M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-9.6M | $-4.5M | $-3.6M | $-1.0M | $2.2M | $7.3M | $4.8M | $8.2M |